Mast Therapeutics begins enrolment for Phase II INABLE-TRAINING study of AIR001 to treat HFpEF
US-based biopharmaceutical company Mast Therapeutics has begun enrolment for its Phase II INABLE-TRAINING study of AIR001 to treat heart failure with preserved ejection fraction (HFpEF).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Cardiology | Heart | Heart Failure | Pharmaceuticals | Study | Training | Universities & Medical Training